Dr Reddy's launches vitamin D analog paricalcitol injection in US

The approved product is the generic version of Abbvie Inc's Zemplar injection

Closures for liquid drugs; Image courtesy: Datwyler
BS B2B Bureau Hyderabad
Last Updated : Sep 20 2016 | 6:33 PM IST
Dr Reddy’s Laboratories Ltd has launched paricalcitol injection in three strengthens - 2 mcg, 5 mcg & 10 mcg – in the US following the marketing approval received by the company from the US Food & Drug Administration (FDA).

The approved product, a synthetically manufactured vitamin D analog, is the generic version of Abbvie Inc’s Zemplar injection. According to IMS Health, the Zemplar brand and generic had US sales of approximately $ 22.5 million MAT for the most recent twelve months ending in July 2016.

Dr Reddy’s paricalcitol injection is the first ANDA product launched in the US market. 

Paricalcitol injection is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease stage 5.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 20 2016 | 9:20 AM IST

Next Story